Diabetes Research and Clinical Practice
Volume 77, Issue 1 , Pages 126-133 , July 2007

Undertreatment of cardiovascular risk factors among persons with diabetes in the United States

  • Shaista Malik

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, Department of Medicine, University of California, Irvine, CA 92697, United States
    • ,
  • Victor Lopez

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, Department of Medicine, University of California, Irvine, CA 92697, United States
    • ,
  • Roland Chen

      Affiliations

    • Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, United States
    • ,
  • Wei Wu

      Affiliations

    • Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, NJ, United States
    • ,
  • Nathan D. Wong

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, Department of Medicine, University of California, Irvine, CA 92697, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 949 824 5561; fax: +1 949 824 5567.

Received 10 August 2006 ,Accepted 17 October 2006.

References 

  1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  2. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004;141:421–431
  3. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(August (7258)):412–419
  4. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  5. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(August (9435)):685–696
  6. Heart Protection Study Collaborative Group . Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  7. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  8. J.R. Downs, M. Clearfield, S.Weis, E.Whitney, D.R. Shapiro, P.A. Beere, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA 279, 1615–1622.
  9. The Cholesterol Recurrent Events (CARE) Study Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The care investigators. Circulation. 1998;98:2513–2519
  10. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diab. Care. 2003;26:2713–2721
  11. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(January (3)):335–342
  12. Imperatore G, Cadwell BL, Geiss L, et al. Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971–2000. Am. J. Epidemiol. 2004;160:531–539
  13. NHANES 1999–2000 Laboratory/Medical Technologists Procedures Manual.
  14. American Diabetes Association. Standards of medical care of diabetes. Diab. Care. 2005;28(Suppl. 1):S4–S36
  15. Jacobs MJ, Kleisli T, Pio J, Malik S, L’Italien GJ, Chen R, et al. Prevalence and treatment of dyslipidemia among persons with diabetes in the United States. Diab. Res. Clin. Pract. 2005;70:263–269
  16. National Diabetes Information Clearinghouse http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm#9 (accessed September 28, 2006).
  17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diab. Care. 2002;25:213–229
  18. Schaars CF, Denig P, Kasje WN, Stewart RE, Wolffenbuttel BH, Haaijer-Ruskamp FM. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diab. Care. 2004;27(January (1)):123–128
  19. Massing MW, Henley NS, Carter-Edwards L, Schenck AP, Simpson RJ. Lipid testing among patients with diabetes who receive diabetes care from primary care physicians. Diab. Care. 2003;26(May (5)):1369–1373
  20. Charpentier G, et al. ESPOIR Diabetes Study Investigators Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diab. Metab. 2003;29:152–158
  21. Massing MW, Foley KA, Sueta CA, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?. Diab. Care. 2003;26:991–997
  22. Ferrara A, et al. Diabetes (TRIAD) Study Group Sex differences in quality of health care related to ischemic heart disease prevention in patients with diabetes: the translating research into action for Diabetes (TRIAD) study 2000–2001. Diab. Care. 2004;27:2974–2976

PII: S0168-8227(06)00487-6

doi: 10.1016/j.diabres.2006.10.016

Diabetes Research and Clinical Practice
Volume 77, Issue 1 , Pages 126-133 , July 2007

Article Tools

* Image Usage & Resolution